Market Overview

UPDATE: Citigroup Upgrades Express Scripts to Buy on Valuation

Share:
Related ESRX
What Are Payors Saying About Managed Care Giants?
Earnings Scheduled For July 28, 2015
UnitedHealth Navigates ObamaCare And Industry M&A (Investor's Business Daily)

Citigroup raised its rating on Express Scripts (NASDAQ: ESRX) from Neutral to Buy and reiterated its $62 price target.

Citigroup commented, "We are upgrading Express Scripts to Buy as the recent sell-off offers a compelling opportunity on a valuation basis. ESRX shares in the last month have sold off 21% versus -4% for the S&P 500 and -2% for its largest PBM competitors CVS Caremark and Catamaran. We are adjusting our estimates that are now above consensus for 2013 and our $62 target price. With the shares trading at less than 12x our 2013 EPS estimate and near a decade-low valuation multiple, ESRX now offers a compelling 24% return to our target price."

Express Scripts closed at $50.05 on Wednesday.

Latest Ratings for ESRX

DateFirmActionFromTo
Jun 2015OppenheimerInitiates Coverage onPerform
Jun 2015Deutsche BankMaintainsHold
Jun 2015Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for ESRX
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ESRX)

Get Benzinga's Newsletters